A single institution review of adjuvant therapy outcomes for resectable pancreatic adenocarcinoma: Outcome and prognostic indicators

Journal of Gastrointestinal Surgery

Volumn 14, Issue 7, 2010, Pages 1159-1169

  Kim, Richard ^a   Tsao, Raymond ^a   Tan, Ann ^a   Byrne, Mike ^b   Almhanna, Khaldoun ^a   Lazaryan, Aleksander ^b   Elson, Paul ^b   Pelley, Robert J ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adjuvant treatment; Chemotherapy; Pancreatic cancer; Radiation

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGE; AGED; ARTICLE; BLOOD; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; PANCREATIC NEOPLASMS; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BILIRUBIN; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77953699277     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-010-1213-z     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. CA Cancer J Clin. 2008; 58(2): 71-96.
2. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995; 221(6): 721-31; discussion 731-733.
3. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg. 1990; 211(4): 447-458.
4. Tsao JI, Rossi RL, Lowell JA. Pylorus-preserving pancreatoduodenectomy. Is it an adequate cancer operation. Arch Surg. 1994; 129(4): 405-412.
5. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial. Lancet. 2001; 358(9293): 1576-1585.
6. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA. 2007; 297(3): 267-277.
7. Hazard L, Tward JD, Szabo A, Shrieve DC. Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: Results of a study from the surveillance, epidemiology, and end results (SEER) registry data. Cancer. 2007; 110(10): 2191-2201.
8. Artinyan A, Hellan M, Mojica-Manosa P, Chen YJ, Pezner R, Ellenhorn JD, et al. Improved survival with adjuvant external-beam radiation therapy in lymph node-negative pancreatic cancer: A united states population-based assessment. Cancer. 2008; 112(1): 34-42.
9. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999; 230(6): 776, 82; discussion 782-4.
10. Burris HA 3 rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 1997; 15(6): 2403-2413.
11. Neuhaus P, Riess H, Post S. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol. 2008; 26. May 20 suppl; abstr LBA4504.
12. Boeck S, Ankerst DP, Heinemann V. The role of adjuvant chemotherapy for patients with resected pancreatic cancer: Systematic review of randomized controlled trials and meta-analysis. Oncology. 2007; 72(5-6): 314-321.
13. Shapiro TM. Adenocarcinoma of the pancreas: A statistical analysis of biliary bypass vs whipple resection in good risk patients. Ann Surg. 1975; 182(6): 715-721.
14. Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the whipple procedure. Ann Surg. 1987; 206(3): 358-365.
15. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990 s: Pathology, complications, and outcomes. Ann Surg. 1997; 226(3): 248-257; discussion 257-60.
16. Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JH, Bakkevold KE, et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: Meta-analysis of randomized controlled trials. Arch Surg. 2008; 143(1): 75-83; discussion 83.
17. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997; 225(5): 621-633; discussion 633-6.
18. Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the johns hopkins hospital. J Clin Oncol. 2008; 26(21): 3503-3510.
19. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA. 2008; 299(9): 1019-1026.
20. Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnell MB, Nagorney DM, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The mayo clinic experience (1975-2005). J Clin Oncol. 2008; 26(21): 3511-3516.
21. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: A population-based, linked database analysis of 396 patients. Ann Surg. 2003; 237(1): 74-85.
22. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006; 244(1): 10-15.
23. Millikan KW, Deziel DJ, Silverstein JC, Kanjo TM, Christein JD, Doolas A, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg. 1999; 65(7): 618-623; discussion 623-4.
24. Winter JM, Cameron JL, Yeo CJ, Alao B, Lillemoe KD, Campbell KA, et al. Biochemical markers predict morbidity and mortality after pancreaticoduodenectomy. J Am Coll Surg. 2007; 204(5): 1029, 36; discussion 1037-8.
25. Schmidt CM, Powell ES, Yiannoutsos CT, Howard TJ, Wiebke EA, Wiesenauer CA, et al. Pancreaticoduodenectomy: A 20-year experience in 516 patients. Arch Surg. 2004; 139(7): 718-725; discussion 725-7.
26. ClinicalTrials. gov. gemcitabine and radiation therapy compared with gemcitabine alone in treating patients who have undergone surgery for pancreatic cancer. available from URL: http://www. clinicaltrials. gov/ct/show/NCT00064207.